person · Reporting owner

CAPPS VICKIE L

Disclosed activity across 8 companies

Tapewire entity: 38791
SEC CIK: 0001248190

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARS Pharmaceuticals, Inc.SBTX · Entity 883	Director	June 10, 2022	June 13, 2022
Janux Therapeutics, Inc.JANX · Entity 4864	Director	June 11, 2026	June 13, 2026
OTONOMY, INC.OTIC · Entity 116495	Director	November 28, 2022	November 29, 2022
Orthofix Medical Inc.OFIX · Entity 1975	Director	June 10, 2026	June 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARS Pharmaceuticals, Inc.

Report date June 10, 2022 · Filed June 13, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2032-06-09	Direct	18,000	Reported balance After 2022-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-10 · Grant · Acquired 18,000 · Balance 18,000 F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Janux Therapeutics, Inc.

Report date June 11, 2026 · Filed June 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	79,598	Reported balance After 2026-06-11 transaction · row 1 1 source row Row 1 · 2026-06-11 · Grant · Acquired 5,500 · Balance 79,598 F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.66 · Expires 2036-06-10	Direct	15,500	Reported balance After 2026-06-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-11 · Grant · Acquired 15,500 · Balance 15,500 F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

OTONOMY, INC.

Report date November 28, 2022 · Filed November 29, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,400	Reported balance After 2022-11-28 transaction · row 1 1 source row Row 1 · 2022-11-28 · Sale · Disposed 42,242 · Balance 3,400 F1: This sale price represents the weighted average sale price of the shares sold ranging from $0.1014 to $0.1031 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Common StockSEC Table I · non-derivative	IndirectBy Spouse	1,600	Reported balance Holding disclosure · report date 2022-11-28 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,600

Filing footnotes · ownership attribution and instrument terms

F1: This sale price represents the weighted average sale price of the shares sold ranging from $0.1014 to $0.1031 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Orthofix Medical Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	43,300	Reported balance After 2026-06-10 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 14,965 · Balance 43,300 F1: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2: Includes 21,934 previously reported deferred stock units and 750 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b).

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.

F2: Includes 21,934 previously reported deferred stock units and 750 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b).

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AMEDISYS INC

Report date August 14, 2025 · Filed August 14, 2025

Section 16 reporting ended · disclosed 2025-08-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-08-14 transaction · row 1 1 source row Row 1 · 2025-08-14 · Disposition to issuer · Disposed 9,818 · Balance 0 F1: On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax. F2: Includes 1,690 time-based Restricted Stock Units ("RSUs") of the Issuer that were outstanding at the Effective Time that were cancelled and converted into the right to receive the Per Share Merger Consideration for each such outstanding RSU as of the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax.

F2: Includes 1,690 time-based Restricted Stock Units ("RSUs") of the Issuer that were outstanding at the Effective Time that were cancelled and converted into the right to receive the Per Share Merger Consideration for each such outstanding RSU as of the Effective Time.

CONNECTURE INC

Report date April 25, 2018 · Filed April 27, 2018

Section 16 reporting ended · disclosed 2018-04-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2018-04-25 transaction · row 1 1 source row Row 1 · 2018-04-25 · Disposition to issuer · Disposed 136,898 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 4, 2018, among Connecture, Inc., FP Healthcare Holdings, Inc. and FP Healthcare Merger Sub Corporation, the shares were cancelled and converted into the right to receive $0.35 in cash, without interest, less any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of January 4, 2018, among Connecture, Inc., FP Healthcare Holdings, Inc. and FP Healthcare Merger Sub Corporation, the shares were cancelled and converted into the right to receive $0.35 in cash, without interest, less any applicable withholding taxes.

NUVASIVE INC

Report date September 01, 2023 · Filed September 05, 2023

Section 16 reporting ended · disclosed 2023-09-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivative	Direct	Reported balance After 2023-09-01 transaction · row 1 1 source row Row 1 · 2023-09-01 · Disposition to issuer · Disposed 2,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-09-01 · Disposition to issuer · Disposed 4,001 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-09-01 · Disposition to issuer · Disposed 2,822 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-09-01 · Disposition to issuer · Disposed 2,130 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-09-01 · Disposition to issuer · Disposed 3,230 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-09-01 · Disposition to issuer · Disposed 2,577 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-09-01 · Disposition to issuer · Disposed 3,095 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-09-01 · Disposition to issuer · Disposed 2,702 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-09-01 · Disposition to issuer · Disposed 3,788 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-09-01 · Disposition to issuer · Disposed 4,816 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-09-01 · Disposition to issuer · Disposed 2,501 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.

F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.

Synthorx, Inc.

Report date January 23, 2020 · Filed January 24, 2020

Section 16 reporting ended · disclosed 2020-01-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2028-05-16	Direct	0	Reported balance After 2020-01-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-01-23 · Disposition to issuer · Disposed 62,412 · Balance 0 F1: This option, which provided for the shares to be immediately exercisable, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $4,185,972.84, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.40 · Expires 2029-06-06	Direct	0	Reported balance After 2020-01-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-23 · Disposition to issuer · Disposed 15,335 · Balance 0 F2: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $852,626, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).

Filing footnotes · ownership attribution and instrument terms

F1: This option, which provided for the shares to be immediately exercisable, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $4,185,972.84, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).

F2: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $852,626, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 11, 2026 Filed Jun 13, 2026 00:00 UTC	Janux Therapeutics, Inc. JANX · Entity 4864	GrantStock Option (right to buy) · Derivative	15,500	$0.00 Strike: $13.66	$0.00	Disclosure SEC source: 0001248190-26-000002 · form4-06122026_080604.xml · derivative · entry 2 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2036-06-10 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. Read SEC document
June 11, 2026 Filed Jun 13, 2026 00:00 UTC	Janux Therapeutics, Inc. JANX · Entity 4864	GrantCommon Stock	5,500	$0.00	$0.00	Disclosure SEC source: 0001248190-26-000002 · form4-06122026_080604.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,598 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. Read SEC document
June 10, 2026 Filed Jun 12, 2026 22:28 UTC	Orthofix Medical Inc. OFIX · Entity 1975	GrantCommon Stock	14,965	$0.00	$0.00	Disclosure SEC source: 0001193125-26-269866 · ownership.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,300 F1 · shares: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2 · balance_after: Includes 21,934 previously reported deferred stock units and 750 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b). Read SEC document
March 10, 2026 Filed Mar 10, 2026 20:13 UTC	Orthofix Medical Inc. OFIX · Entity 1975	PurchaseCommon Stock	2,400	$12.45	$29,880.00	Disclosure SEC source: 0001193125-26-100156 · ownership.xml · nonDerivative · entry 3 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,585 F1 · balance_after: Includes 21,934 previously reported deferred stock units and 651 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 10/31/2025. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b). Read SEC document
March 10, 2026 Filed Mar 10, 2026 20:13 UTC	Orthofix Medical Inc. OFIX · Entity 1975	PurchaseCommon Stock	100	$12.44	$1,244.00	Disclosure SEC source: 0001193125-26-100156 · ownership.xml · nonDerivative · entry 2 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,185 F1 · balance_after: Includes 21,934 previously reported deferred stock units and 651 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 10/31/2025. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b). Read SEC document
March 09, 2026 Filed Mar 10, 2026 20:13 UTC	Orthofix Medical Inc. OFIX · Entity 1975	PurchaseCommon Stock	2,500	$12.48	$31,200.00	Disclosure SEC source: 0001193125-26-100156 · ownership.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,085 F1 · balance_after: Includes 21,934 previously reported deferred stock units and 651 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 10/31/2025. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b). Read SEC document
August 14, 2025 Filed Aug 14, 2025 16:02 UTC	AMEDISYS INC AMED · Entity 16075	Disposition to issuerCommon Stock	9,818	Not disclosed	Not disclosed	Disclosure SEC source: 0000896262-25-000082 · wk-form4_1755201754.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax. F2 · shares: Includes 1,690 time-based Restricted Stock Units ("RSUs") of the Issuer that were outstanding at the Effective Time that were cancelled and converted into the right to receive the Per Share Merger Consideration for each such outstanding RSU as of the Effective Time. F1 · price: On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax. F2 · price: Includes 1,690 time-based Restricted Stock Units ("RSUs") of the Issuer that were outstanding at the Effective Time that were cancelled and converted into the right to receive the Per Share Merger Consideration for each such outstanding RSU as of the Effective Time. Read SEC document
June 18, 2025 Filed Jun 23, 2025 20:18 UTC	Orthofix Medical Inc. OFIX · Entity 1975	GrantCommon Stock	18,841	$0.00	$0.00	Disclosure SEC source: 0000950170-25-088996 · ownership.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,934 F1 · shares: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2 · balance_after: Includes 3,093 previously reported deferred stock units. Read SEC document
June 11, 2025 Filed Jun 13, 2025 23:30 UTC	Janux Therapeutics, Inc. JANX · Entity 4864	GrantStock Option (right to buy) · Derivative	11,667	$0.00 Strike: $25.46	$0.00	Disclosure SEC source: 0001415889-25-017316 · form4-06132025_070614.xml · derivative · entry 2 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,667 Underlying: Common Stock · 11,667 shares Expires 2035-06-10 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. Read SEC document
June 11, 2025 Filed Jun 13, 2025 23:30 UTC	Janux Therapeutics, Inc. JANX · Entity 4864	GrantCommon Stock	3,750	$0.00	$0.00	Disclosure SEC source: 0001415889-25-017316 · form4-06132025_070614.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,098 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. Read SEC document
May 03, 2025 Filed May 6, 2025 19:48 UTC	AMEDISYS INC AMED · Entity 16075	GrantCommon Stock	1,690	$0.00	$0.00	Disclosure SEC source: 0000896262-25-000043 · wk-form4_1746575325.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,818 F1 · shares: The Issuer awarded the Reporting Person 1,690 time-based Restricted Stock Units, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest 100% on May 3, 2026, predicated upon the Reporting Person's continued service as a non-employee member of the Issuer's Board of Directors through the vesting date. Read SEC document
March 11, 2025 Filed Mar 13, 2025 20:21 UTC	Orthofix Medical Inc. OFIX · Entity 1975	GrantEmployee Stock Option (Right to Buy) · Derivative	35,270	$0.00 Strike: $17.10	$0.00	Disclosure SEC source: 0000950170-25-038774 · ownership.xml · derivative · entry 2 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,270 Underlying: Common Stock · 35,270 shares Expires 2035-03-11 F2 · derivative.exercise_date: The options vest and become exercisable with respect to 25% of the shares covered thereby on the first, second, third and fourth anniversary of the Grant Date. Read SEC document
March 11, 2025 Filed Mar 13, 2025 20:21 UTC	Orthofix Medical Inc. OFIX · Entity 1975	GrantCommon Stock	3,093	$0.00	$0.00	Disclosure SEC source: 0000950170-25-038774 · ownership.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,093 F1 · shares: Represents an award of deferred stock units that vest in full on the earlier of (i) June 30, 2025 or (ii) the date on which the issuer holds its 2025 annual meeting of stockholders, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. Read SEC document
November 05, 2024 Filed Nov 8, 2024 00:08 UTC	Janux Therapeutics, Inc. JANX · Entity 4864	OtherCommon Stock	2,305	$0.00	$0.00	Disclosure SEC source: 0001415889-24-026385 · form4-11082024_121119.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,348 F1 · kind: Represents receipt of securities in a pro rata, in-kind distribution of securities, by ABV SPV I GP LLC, of which Reporting Person is a member. Read SEC document
June 26, 2024 Filed Jun 28, 2024 20:30 UTC	Janux Therapeutics, Inc. JANX · Entity 4864	GrantStock Option (right to buy) · Derivative	8,350	$0.00 Strike: $39.80	$0.00	Disclosure SEC source: 0001415889-24-018437 · form4-06282024_040633.xml · derivative · entry 2 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,350 Underlying: Common Stock · 8,350 shares Expires 2034-06-25 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. Read SEC document
June 26, 2024 Filed Jun 28, 2024 20:30 UTC	Janux Therapeutics, Inc. JANX · Entity 4864	GrantCommon Stock	2,500	$0.00	$0.00	Disclosure SEC source: 0001415889-24-018437 · form4-06282024_040633.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,043 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. Read SEC document
May 03, 2024 Filed May 7, 2024 20:59 UTC	AMEDISYS INC AMED · Entity 16075	GrantCommon Stock	1,678	$0.00	$0.00	Disclosure SEC source: 0000896262-24-000028 · wk-form4_1715129984.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,128 F1 · shares: The Issuer awarded the Reporting Person 1,678 time-based Restricted Stock Units, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest 100% on May 3, 2025, predicated upon the Reporting Person's continued service as a non-employee member of the Issuer's Board of Directors through the vesting date. Read SEC document
February 29, 2024 Filed Mar 4, 2024 21:33 UTC	Janux Therapeutics, Inc. JANX · Entity 4864	OtherCommon Stock	1,493	$0.00	$0.00	Disclosure SEC source: 0001415889-24-006293 · form4-03042024_090300.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,543 F1 · kind: Represents receipt of securities in a pro rata, in-kind distribution of securities, by ABV SPV I GP LLC, of which Reporting Person is a member. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:39 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	4,816	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048177 · doc4.xml · derivative · entry 11 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,816 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:39 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	3,788	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048177 · doc4.xml · derivative · entry 10 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,788 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:39 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	2,702	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048177 · doc4.xml · derivative · entry 9 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,702 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:39 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	3,095	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048177 · doc4.xml · derivative · entry 8 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,095 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:39 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	2,577	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048177 · doc4.xml · derivative · entry 7 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,577 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:39 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	3,230	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048177 · doc4.xml · derivative · entry 6 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,230 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:39 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	2,130	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048177 · doc4.xml · derivative · entry 5 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,130 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:39 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	2,822	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048177 · doc4.xml · derivative · entry 4 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,822 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:39 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Units · Derivative	2,501	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048177 · doc4.xml · derivative · entry 3 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,501 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:39 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	4,001	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048177 · doc4.xml · derivative · entry 2 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,001 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:39 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerCommon Stock, par value $0.001 per share	2,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-048177 · doc4.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares. Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:06 UTC	Janux Therapeutics, Inc. JANX · Entity 4864	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $13.22	$0.00	Disclosure SEC source: 0001209191-23-037975 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders. Read SEC document
June 09, 2023 Filed Jun 12, 2023 17:42 UTC	NUVASIVE INC NUVA · Entity 110002	GrantRSUs · Derivative	4,816	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-23-036439 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,816 Underlying: Common Stock · 4,816 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2024 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F3 · derivative.exercise_date: On February 8, 2023, Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Globus Medical, Inc. ("Globus Medical") and Zebra Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Globus Medical. The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Globus Medical. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each RSU outstanding immediately prior to the Effective Time held by the Reporting Person will fully vest and be cancelled and converted automatically into the right to receive (without interest) 0.75 fully paid and non-assessable shares of Class A common stock of Globus Medical (and cash in lieu of any fractional shares) in respect of each share of Issuer's common stock underlying such RSU. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2024 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F3 · derivative.expiration_date: On February 8, 2023, Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Globus Medical, Inc. ("Globus Medical") and Zebra Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Globus Medical. The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Globus Medical. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each RSU outstanding immediately prior to the Effective Time held by the Reporting Person will fully vest and be cancelled and converted automatically into the right to receive (without interest) 0.75 fully paid and non-assessable shares of Class A common stock of Globus Medical (and cash in lieu of any fractional shares) in respect of each share of Issuer's common stock underlying such RSU. Read SEC document
May 03, 2023 Filed May 5, 2023 21:21 UTC	AMEDISYS INC AMED · Entity 16075	GrantCommon Stock	1,941	$0.00	$0.00	Disclosure SEC source: 0000896262-23-000046 · wf-form4_168333608700996.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,450 F1 · shares: The Issuer awarded the Reporting Person 1,941 time-based Restricted Stock Units, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest 100% on May 3, 2024, predicated upon the Reporting Person's continued service as a non-employee member of the Issuer's Board of Directors through the vesting date. Read SEC document
November 28, 2022 Filed Nov 29, 2022 16:18 UTC	OTONOMY, INC. OTIC · Entity 116495	SaleCommon Stock	42,242	$0.10	$4,342.48	Disclosure SEC source: 0001209191-22-058939 · doc4.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,400 F1 · price: This sale price represents the weighted average sale price of the shares sold ranging from $0.1014 to $0.1031 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
June 21, 2022 Filed Jun 23, 2022 16:31 UTC	OTONOMY, INC. OTIC · Entity 116495	GrantStock Option (right to buy) · Derivative	27,500	$0.00 Strike: $1.95	$0.00	Disclosure SEC source: 0001209191-22-038885 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2032-06-20 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date. Read SEC document
June 14, 2022 Filed Jun 16, 2022 20:37 UTC	Janux Therapeutics, Inc. JANX · Entity 4864	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $10.73	$0.00	Disclosure SEC source: 0001209191-22-037449 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-13 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2022, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders. Read SEC document
June 10, 2022 Filed Jun 13, 2022 23:27 UTC	ARS Pharmaceuticals, Inc. SBTX · Entity 883	GrantStock Option (right to buy) · Derivative	18,000	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001209191-22-036471 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document
June 09, 2022 Filed Jun 13, 2022 16:37 UTC	AMEDISYS INC AMED · Entity 16075	GrantCommon Stock	1,304	$0.00	$0.00	Disclosure SEC source: 0000896262-22-000040 · wf-form4_165515265381015.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,509 F1 · shares: The Issuer awarded the Reporting Person 1,304 time-based Restricted Stock Units, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest 100% on June 9, 2023, predicated upon the Reporting Person's continued service as a non-employee member of the Issuer's Board of Directors through the vesting date. Read SEC document
May 11, 2022 Filed May 13, 2022 17:44 UTC	NUVASIVE INC NUVA · Entity 110002	GrantRSUs · Derivative	3,788	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-22-028931 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,788 Underlying: Common Stock · 3,788 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2023 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2023 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document
June 22, 2021 Filed Jun 24, 2021 17:01 UTC	OTONOMY, INC. OTIC · Entity 116495	GrantStock Option (right to buy) · Derivative	17,500	$0.00 Strike: $2.18	$0.00	Disclosure SEC source: 0001209191-21-043071 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-21 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date. Read SEC document
June 08, 2021 Filed Jun 10, 2021 17:55 UTC	AMEDISYS INC AMED · Entity 16075	GrantCommon Stock	574	$0.00	$0.00	Disclosure SEC source: 0000896262-21-000087 · wf-form4_162336208447964.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,205 F1 · shares: The Issuer awarded the Reporting Person 574 time-based Restricted Stock Units, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest 100% on June 8, 2022, predicated upon the Reporting Person's continued service as a non-employee member of the Issuer's Board of Directors through the vesting date. Read SEC document
June 04, 2021 Filed Sep 21, 2021 21:03 UTC	ARS Pharmaceuticals, Inc. SBTX · Entity 883	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $28.83	$0.00	Disclosure SEC source: 0001209191-21-057055 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 4, 2022 or the date of the 2022 annual meeting of the Issuer's stockholders which date has not been set by the Issuer's Board of Directors. Read SEC document
May 18, 2021 Filed May 20, 2021 17:43 UTC	NUVASIVE INC NUVA · Entity 110002	GrantRSUs · Derivative	2,702	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-21-034535 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,702 Underlying: Common Stock · 2,702 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2022 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2022 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document
December 08, 2020 Filed Dec 9, 2020 01:56 UTC	ARS Pharmaceuticals, Inc. SBTX · Entity 883	PurchaseCommon Stock	9,523	$21.00	$199,983.00	Disclosure SEC source: 0001209191-20-062404 · doc4.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,576 F1 · kind: The shares were purchased in the Issuer's initial public offering. Read SEC document
December 03, 2020 Filed Dec 8, 2020 00:47 UTC	ARS Pharmaceuticals, Inc. SBTX · Entity 883	GrantEmployee Stock Option Right to Buy · Derivative	38,405	$0.00 Strike: $21.00	$0.00	Disclosure SEC source: 0001209191-20-062043 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,405 Underlying: Common Stock · 38,405 shares Expires 2030-12-02 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 36 months following December 3, 2020. Read SEC document
November 09, 2020 Filed Nov 10, 2020 17:48 UTC	NUVASIVE INC NUVA · Entity 110002	PurchaseCommon Stock	2,000	$48.23	$96,460.00	Disclosure SEC source: 0001209191-20-057723 · doc4.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · price: Weighted average purchase price from purchase transactions ranging from $48.21 to $48.23. Upon request by the Commission staff, the Issuer or a security holder of the Issuer, the Reporting Person will undertake to provide full information regarding the number of shares purchased at each separate price. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards, including vested awards for which delivery has been deferred. Read SEC document
June 23, 2020 Filed Jun 25, 2020 17:04 UTC	OTONOMY, INC. OTIC · Entity 116495	GrantStock Option (right to buy) · Derivative	17,500	$0.00 Strike: $3.56	$0.00	Disclosure SEC source: 0001209191-20-038939 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2030-06-22 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date. Read SEC document
June 09, 2020 Filed Jun 11, 2020 21:01 UTC	AMEDISYS INC AMED · Entity 16075	GrantCommon Stock	851	$0.00	$0.00	Disclosure SEC source: 0000899243-20-016244 · doc4.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,631 F1 · shares: The Issuer awarded the Reporting Person 851 time-based Restricted Stock Units, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest 100% on June 9, 2021, predicated upon the Reporting Person's continued service as a non-employee member of the Issuer's Board of Directors through the vesting date. Read SEC document
May 28, 2020 Filed May 29, 2020 17:42 UTC	NUVASIVE INC NUVA · Entity 110002	GrantRSUs · Derivative	3,095	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-20-032995 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,095 Underlying: Common Stock · 3,095 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2021 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2021 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document
February 25, 2020 Filed Feb 26, 2020 21:00 UTC	AMEDISYS INC AMED · Entity 16075	PurchaseCommon Stock	1,000	$187.00	$187,000.00	Disclosure SEC source: 0000899243-20-005983 · doc4.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,780 Read SEC document
January 23, 2020 Filed Jan 24, 2020 18:20 UTC	Synthorx, Inc. THOR · Entity 152202	Disposition to issuerStock Option (right to buy) · Derivative	15,335	$55.60 Strike: $12.40	$852,626.00	Disclosure SEC source: 0001209191-20-004920 · doc4.xml · derivative · entry 2 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,335 shares Expires 2029-06-06 F2 · derivative.exercise_date: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $852,626, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.